Sounds consistent with what they said last August. A new report was issued today, but access is restricted to Hambrecht clients... wrhambrecht.com
+++++++++
Cell Therapeutics initiated with "buy"
Tuesday, August 10, 2004 8:19:30 AM ET
WR Hambrecht & Co
NEW YORK, August 10 – Analysts at WR Hambrecht initiate coverage of Cell Therapeutics Inc (CTIC.NAS) with a "buy" rating. The target price is set to $16.
In a research note published this morning, the analysts mention that the company’s product pipeline is extremely promising. Positive data for Xyotax’s Phase III trials for lung cancer, for Pixantrone’s study in relapsed aggressive non-Hodgkin's lymphoma and for Trisenox in new indications would drive Cell Therapeutics’ stock performance over the next 6-18 months, the analysts believe.
++++++++++++++++++++++++++++++
CIBC World Markets Corp. (CTIC)
10 January 2005, 05:54am ET
CTIC: Reit Sector Outperformer - On 1/07, APPX (SO) reported FDA approval of its albumin-bound paclitaxel suspension ABRAXANE for second-line metastatic breast cancer (BC). This modified formulation of paclitaxel, like CTIC`s polyglutamated paclitaxel Xyotax, permits higher chemo dosing with less solvent-related toxicity. This news indicates that the FDA is willing to approve a modified Taxol compound with better responses but a side effect profile worse in some respects. We believe this lowers the bar for compounds like Xyotax, which is positive for CTIC stock. |
